Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review (Q34311370)

1 August 2017

1 reference

title

Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review (English)

1 reference

pancreatic adenocarcinoma

1 August 2017

1 reference

1 reference

metastatic pancreatic adenocarcinoma

inferred from title

1 reference

P Kozuch

1

1 reference

1 August 2017

M Petryk

series ordinal

2

1 reference

1 August 2017

A Evans

series ordinal

3

1 reference

1 August 2017

H W Bruckner

series ordinal

4

1 reference

1 August 2017

publication date

1 June 2001

1 reference

Surgical Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

81

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

683-690

1 reference

Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Phase II trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

The spectrum of chemosensitivity of two human pancreatic carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Chemotherapy in the treatment of cancer of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2805%2970153-5

7 January 2021

10.1016/S0039-6109(05)70153-5

Identifiers

DOI

1 reference

1 August 2017

1 reference